ID   ZBT16_HUMAN             Reviewed;         673 AA.
AC   Q05516; Q8TAL4;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 2.
DT   28-JUN-2023, entry version 232.
DE   RecName: Full=Zinc finger and BTB domain-containing protein 16;
DE   AltName: Full=Promyelocytic leukemia zinc finger protein;
DE   AltName: Full=Zinc finger protein 145;
DE   AltName: Full=Zinc finger protein PLZF;
GN   Name=ZBTB16; Synonyms=PLZF, ZNF145;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PLZFB), ALTERNATIVE SPLICING, AND
RP   CHROMOSOMAL TRANSLOCATION WITH RARA.
RC   TISSUE=Heart ventricle;
RX   PubMed=8384553; DOI=10.1002/j.1460-2075.1993.tb05757.x;
RA   Chen Z., Brand N.J., Chen A., Chen S.-J., Tong J.-H., Wang Z.-Y.,
RA   Waxman S., Zelent A.;
RT   "Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid
RT   receptor-alpha locus due to a variant t(11;17) translocation associated
RT   with acute promyelocytic leukaemia.";
RL   EMBO J. 12:1161-1167(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10500192; DOI=10.1073/pnas.96.20.11422;
RA   Zhang T., Xiong H., Kan L.-X., Zhang C.-K., Jiao X.-F., Fu G., Zhang Q.-H.,
RA   Lu L., Tong J.-H., Gu B.-W., Yu M., Liu J.-X., Licht J., Waxman S.,
RA   Zelent A., Chen E., Chen S.-J.;
RT   "Genomic sequence, structural organization, molecular evolution, and
RT   aberrant rearrangement of promyelocytic leukemia zinc finger gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:11422-11427(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PLZFB).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 424-455.
RX   PubMed=8387545; DOI=10.1172/jci116453;
RA   Chen S.-J., Zelent A., Tong J.-H., Yu H.-Q., Wang Z.-Y., Derre J.,
RA   Berger R., Waxman S., Chen Z.;
RT   "Rearrangements of the retinoic acid receptor alpha and promyelocytic
RT   leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient
RT   with acute promyelocytic leukemia.";
RL   J. Clin. Invest. 91:2260-2267(1993).
RN   [5]
RP   INTERACTION WITH ZBTB32.
RX   PubMed=10572087;
RA   Hoatlin M.E., Zhi Y., Ball H., Silvey K., Melnick A., Stone S., Arai S.,
RA   Hawe N., Owen G., Zelent A., Licht J.D.;
RT   "A novel BTB/POZ transcriptional repressor protein interacts with the
RT   Fanconi anemia group C protein and PLZF.";
RL   Blood 94:3737-3747(1999).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH RUNX1T1.
RX   PubMed=10688654; DOI=10.1128/mcb.20.6.2075-2086.2000;
RA   Melnick A.M., Westendorf J.J., Polinger A., Carlile G.W., Arai S.,
RA   Ball H.J., Lutterbach B., Hiebert S.W., Licht J.D.;
RT   "The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is
RT   a corepressor for the promyelocytic leukemia zinc finger protein.";
RL   Mol. Cell. Biol. 20:2075-2086(2000).
RN   [7]
RP   INTERACTION WITH EPN1.
RX   PubMed=11161217; DOI=10.1126/science.291.5506.1047;
RA   Itoh T., Koshiba S., Kigawa T., Kikuchi A., Yokoyama S., Takenawa T.;
RT   "Role of the ENTH domain in phosphatidylinositol-4,5-bisphosphate binding
RT   and endocytosis.";
RL   Science 291:1047-1051(2001).
RN   [8]
RP   FUNCTION AS AN E3 UBIQUITIN-PROTEIN LIGASE, AND INTERACTION WITH CUL3.
RX   PubMed=14528312; DOI=10.1038/ncb1056;
RA   Furukawa M., He Y.J., Borchers C., Xiong Y.;
RT   "Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin
RT   ligases.";
RL   Nat. Cell Biol. 5:1001-1007(2003).
RN   [9]
RP   INTERACTION WITH ATP7B.
RX   PubMed=16676348; DOI=10.1002/jcb.20980;
RA   Ko J.H., Son W., Bae G.Y., Kang J.H., Oh W., Yoo O.J.;
RT   "A new hepatocytic isoform of PLZF lacking the BTB domain interacts with
RT   ATP7B, the Wilson disease protein, and positively regulates ERK signal
RT   transduction.";
RL   J. Cell. Biochem. 99:719-734(2006).
RN   [10]
RP   FUNCTION, INTERACTION WITH RNF112, AND SUBCELLULAR LOCATION.
RX   PubMed=24359566; DOI=10.1186/1423-0127-20-98;
RA   Lin D.Y., Huang C.C., Hsieh Y.T., Lin H.C., Pao P.C., Tsou J.H., Lai C.Y.,
RA   Hung L.Y., Wang J.M., Chang W.C., Lee Y.C.;
RT   "Analysis of the interaction between Zinc finger protein 179 (Znf179) and
RT   promyelocytic leukemia zinc finger (Plzf).";
RL   J. Biomed. Sci. 20:98-98(2013).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 6-126.
RX   PubMed=9770450; DOI=10.1073/pnas.95.21.12123;
RA   Ahmad K.F., Engel C.K., Prive G.G.;
RT   "Crystal structure of the BTB domain from PLZF.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:12123-12128(1998).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 7-122.
RX   PubMed=10537309;
RA   Li X., Peng H., Schultz D.C., Lopez-Guisa J.M., Rauscher F.J. III,
RA   Marmorstein R.;
RT   "Structure-function studies of the BTB/POZ transcriptional repression
RT   domain from the promyelocytic leukemia zinc finger oncoprotein.";
RL   Cancer Res. 59:5275-5282(1999).
RN   [13]
RP   VARIANT SGYMR VAL-617.
RX   PubMed=18611983; DOI=10.1136/jmg.2008.059451;
RA   Fischer S., Kohlhase J., Boehm D., Schweiger B., Hoffmann D., Heitmann M.,
RA   Horsthemke B., Wieczorek D.;
RT   "Biallelic loss of function of the promyelocytic leukaemia zinc finger
RT   (PLZF) gene causes severe skeletal defects and genital hypoplasia.";
RL   J. Med. Genet. 45:731-737(2008).
CC   -!- FUNCTION: Acts as a transcriptional repressor (PubMed:10688654,
CC       PubMed:24359566). Transcriptional repression may be mediated through
CC       recruitment of histone deacetylases to target promoters
CC       (PubMed:10688654). May play a role in myeloid maturation and in the
CC       development and/or maintenance of other differentiated tissues.
CC       Probable substrate-recognition component of an E3 ubiquitin-protein
CC       ligase complex which mediates the ubiquitination and subsequent
CC       proteasomal degradation of target proteins (PubMed:14528312).
CC       {ECO:0000269|PubMed:10688654, ECO:0000269|PubMed:14528312,
CC       ECO:0000269|PubMed:24359566}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Binds EPN1 (PubMed:11161217). Interacts with ZBTB32 and CUL3
CC       (PubMed:10572087, PubMed:14528312). Interacts with ATP7B
CC       (PubMed:16676348). Interacts with transcriptional corepressor RUNX1T1
CC       (via its N-terminus); the interaction increases the transcription
CC       repression activity of ZBTB16 (PubMed:10688654). Interacts (via C2H2-
CC       type zinc finger domains 1 and 2) with RNF112 (PubMed:24359566).
CC       {ECO:0000269|PubMed:10572087, ECO:0000269|PubMed:10688654,
CC       ECO:0000269|PubMed:11161217, ECO:0000269|PubMed:14528312,
CC       ECO:0000269|PubMed:16676348, ECO:0000269|PubMed:24359566}.
CC   -!- INTERACTION:
CC       Q05516; Q9Y2J4: AMOTL2; NbExp=3; IntAct=EBI-711925, EBI-746752;
CC       Q05516; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-711925, EBI-2548012;
CC       Q05516; Q9H257-2: CARD9; NbExp=3; IntAct=EBI-711925, EBI-11530605;
CC       Q05516; Q8TD31-3: CCHCR1; NbExp=3; IntAct=EBI-711925, EBI-10175300;
CC       Q05516; Q8NHQ1: CEP70; NbExp=4; IntAct=EBI-711925, EBI-739624;
CC       Q05516; Q9Y2V7: COG6; NbExp=5; IntAct=EBI-711925, EBI-3866319;
CC       Q05516; Q9GZU7: CTDSP1; NbExp=3; IntAct=EBI-711925, EBI-751587;
CC       Q05516; P68104: EEF1A1; NbExp=4; IntAct=EBI-711925, EBI-352162;
CC       Q05516; Q5JST6: EFHC2; NbExp=3; IntAct=EBI-711925, EBI-2349927;
CC       Q05516; Q9NTX9: FAM217B; NbExp=3; IntAct=EBI-711925, EBI-19153639;
CC       Q05516; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-711925, EBI-6658203;
CC       Q05516; Q5TD97: FHL5; NbExp=3; IntAct=EBI-711925, EBI-750641;
CC       Q05516; Q08379: GOLGA2; NbExp=8; IntAct=EBI-711925, EBI-618309;
CC       Q05516; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-711925, EBI-5916454;
CC       Q05516; O95872: GPANK1; NbExp=3; IntAct=EBI-711925, EBI-751540;
CC       Q05516; Q13547: HDAC1; NbExp=2; IntAct=EBI-711925, EBI-301834;
CC       Q05516; P07686: HEXB; NbExp=3; IntAct=EBI-711925, EBI-7133736;
CC       Q05516; P49639: HOXA1; NbExp=3; IntAct=EBI-711925, EBI-740785;
CC       Q05516; Q00444: HOXC5; NbExp=3; IntAct=EBI-711925, EBI-11955357;
CC       Q05516; O75031: HSF2BP; NbExp=3; IntAct=EBI-711925, EBI-7116203;
CC       Q05516; P42858: HTT; NbExp=4; IntAct=EBI-711925, EBI-466029;
CC       Q05516; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-711925, EBI-14069005;
CC       Q05516; Q6A162: KRT40; NbExp=9; IntAct=EBI-711925, EBI-10171697;
CC       Q05516; A0A0C4DGV4: LAMTOR5; NbExp=6; IntAct=EBI-711925, EBI-10173304;
CC       Q05516; O95751: LDOC1; NbExp=4; IntAct=EBI-711925, EBI-740738;
CC       Q05516; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-711925, EBI-16439278;
CC       Q05516; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-711925, EBI-10172526;
CC       Q05516; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-711925, EBI-11522433;
CC       Q05516; Q8WY64: MYLIP; NbExp=3; IntAct=EBI-711925, EBI-6952711;
CC       Q05516; Q8NI38: NFKBID; NbExp=3; IntAct=EBI-711925, EBI-10271199;
CC       Q05516; O00746: NME4; NbExp=3; IntAct=EBI-711925, EBI-744871;
CC       Q05516; Q9H4L5: OSBPL3; NbExp=3; IntAct=EBI-711925, EBI-1051317;
CC       Q05516; O43189: PHF1; NbExp=3; IntAct=EBI-711925, EBI-530034;
CC       Q05516; O75928-2: PIAS2; NbExp=3; IntAct=EBI-711925, EBI-348567;
CC       Q05516; Q4G0R1: PIBF1; NbExp=3; IntAct=EBI-711925, EBI-14066006;
CC       Q05516; P29590: PML; NbExp=7; IntAct=EBI-711925, EBI-295890;
CC       Q05516; P29590-5: PML; NbExp=2; IntAct=EBI-711925, EBI-304008;
CC       Q05516; P31321: PRKAR1B; NbExp=3; IntAct=EBI-711925, EBI-2805516;
CC       Q05516; Q96QF0-7: RAB3IP; NbExp=3; IntAct=EBI-711925, EBI-11984839;
CC       Q05516; Q04864-2: REL; NbExp=3; IntAct=EBI-711925, EBI-10829018;
CC       Q05516; Q6NUQ1: RINT1; NbExp=3; IntAct=EBI-711925, EBI-726876;
CC       Q05516; Q9H788-2: SH2D4A; NbExp=3; IntAct=EBI-711925, EBI-10308083;
CC       Q05516; Q9NYJ8: TAB2; NbExp=3; IntAct=EBI-711925, EBI-358708;
CC       Q05516; Q08117-2: TLE5; NbExp=3; IntAct=EBI-711925, EBI-11741437;
CC       Q05516; Q13077: TRAF1; NbExp=5; IntAct=EBI-711925, EBI-359224;
CC       Q05516; Q12933: TRAF2; NbExp=5; IntAct=EBI-711925, EBI-355744;
CC       Q05516; Q9BUZ4: TRAF4; NbExp=3; IntAct=EBI-711925, EBI-3650647;
CC       Q05516; P19474: TRIM21; NbExp=3; IntAct=EBI-711925, EBI-81290;
CC       Q05516; P36406: TRIM23; NbExp=3; IntAct=EBI-711925, EBI-740098;
CC       Q05516; P14373: TRIM27; NbExp=5; IntAct=EBI-711925, EBI-719493;
CC       Q05516; Q9BYV2: TRIM54; NbExp=6; IntAct=EBI-711925, EBI-2130429;
CC       Q05516; Q5W5X9-3: TTC23; NbExp=3; IntAct=EBI-711925, EBI-9090990;
CC       Q05516; Q7KZS0: UBE2I; NbExp=3; IntAct=EBI-711925, EBI-10180829;
CC       Q05516; Q9NP79: VTA1; NbExp=4; IntAct=EBI-711925, EBI-740160;
CC       Q05516; Q05516: ZBTB16; NbExp=8; IntAct=EBI-711925, EBI-711925;
CC       Q05516; B2RXF5: ZBTB42; NbExp=3; IntAct=EBI-711925, EBI-12287587;
CC       Q05516; Q9H707: ZNF552; NbExp=3; IntAct=EBI-711925, EBI-2555731;
CC       Q05516; Q6ZNG0: ZNF620; NbExp=3; IntAct=EBI-711925, EBI-4395669;
CC       Q05516; Q8N720: ZNF655; NbExp=3; IntAct=EBI-711925, EBI-625509;
CC       Q05516; O35826: Gne; Xeno; NbExp=2; IntAct=EBI-711925, EBI-7109445;
CC       Q05516; P09022: Hoxa1; Xeno; NbExp=3; IntAct=EBI-711925, EBI-3957603;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24359566}. Nucleus,
CC       nuclear body {ECO:0000269|PubMed:24359566}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=PLZFB;
CC         IsoId=Q05516-1; Sequence=Displayed;
CC       Name=PLZFA;
CC         IsoId=Q05516-2; Sequence=VSP_006896;
CC   -!- TISSUE SPECIFICITY: Within the hematopoietic system, PLZF is expressed
CC       in bone marrow, early myeloid cell lines and peripheral blood
CC       mononuclear cells. Also expressed in the ovary, and at lower levels, in
CC       the kidney and lung.
CC   -!- INDUCTION: By retinoic acid.
CC   -!- DISEASE: Skeletal defects, genital hypoplasia, and impaired
CC       intellectual development (SGYMR) [MIM:612447]: A disorder characterized
CC       by intellectual disability, craniofacial dysmorphism, microcephaly and
CC       short stature. Additional features include absence of the thumbs,
CC       hypoplasia of the radii and ulnae, additional vertebrae and ribs,
CC       retarded bone age and genital hypoplasia.
CC       {ECO:0000269|PubMed:18611983}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving ZBTB16 may be a cause
CC       of acute promyelocytic leukemia (APL). Translocation t(11;17)(q32;q21)
CC       with RARA. {ECO:0000269|PubMed:8384553}.
CC   -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/37/PLZF";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z19002; CAA79489.1; -; mRNA.
DR   EMBL; AF060568; AAD03619.1; -; Genomic_DNA.
DR   EMBL; BC026902; AAH26902.1; -; mRNA.
DR   EMBL; BC029812; AAH29812.1; -; mRNA.
DR   EMBL; S60093; AAC60590.2; -; Genomic_DNA.
DR   CCDS; CCDS8367.1; -. [Q05516-1]
DR   PIR; S36336; S36336.
DR   RefSeq; NP_001018011.1; NM_001018011.1. [Q05516-1]
DR   RefSeq; NP_005997.2; NM_006006.4. [Q05516-1]
DR   RefSeq; XP_016873746.1; XM_017018257.1.
DR   RefSeq; XP_016873747.1; XM_017018258.1.
DR   RefSeq; XP_016873748.1; XM_017018259.1.
DR   PDB; 1BUO; X-ray; 1.90 A; A=6-126.
DR   PDB; 1CS3; X-ray; 2.00 A; A=7-122.
DR   PDBsum; 1BUO; -.
DR   PDBsum; 1CS3; -.
DR   AlphaFoldDB; Q05516; -.
DR   SMR; Q05516; -.
DR   BioGRID; 113498; 172.
DR   DIP; DIP-2654N; -.
DR   IntAct; Q05516; 124.
DR   MINT; Q05516; -.
DR   STRING; 9606.ENSP00000338157; -.
DR   BindingDB; Q05516; -.
DR   ChEMBL; CHEMBL4105726; -.
DR   MoonDB; Q05516; Predicted.
DR   iPTMnet; Q05516; -.
DR   PhosphoSitePlus; Q05516; -.
DR   BioMuta; ZBTB16; -.
DR   DMDM; 90109930; -.
DR   EPD; Q05516; -.
DR   MassIVE; Q05516; -.
DR   PaxDb; Q05516; -.
DR   PeptideAtlas; Q05516; -.
DR   ProteomicsDB; 58332; -. [Q05516-1]
DR   ProteomicsDB; 58333; -. [Q05516-2]
DR   ABCD; Q05516; 3 sequenced antibodies.
DR   Antibodypedia; 897; 427 antibodies from 38 providers.
DR   DNASU; 7704; -.
DR   Ensembl; ENST00000335953.9; ENSP00000338157.4; ENSG00000109906.15. [Q05516-1]
DR   Ensembl; ENST00000392996.2; ENSP00000376721.2; ENSG00000109906.15. [Q05516-1]
DR   Ensembl; ENST00000682278.1; ENSP00000506794.1; ENSG00000109906.15. [Q05516-1]
DR   Ensembl; ENST00000682697.1; ENSP00000506924.1; ENSG00000109906.15. [Q05516-1]
DR   Ensembl; ENST00000682971.1; ENSP00000506894.1; ENSG00000109906.15. [Q05516-1]
DR   Ensembl; ENST00000683318.1; ENSP00000508351.1; ENSG00000109906.15. [Q05516-1]
DR   Ensembl; ENST00000683554.1; ENSP00000506953.1; ENSG00000109906.15. [Q05516-1]
DR   Ensembl; ENST00000684295.1; ENSP00000507788.1; ENSG00000109906.15. [Q05516-1]
DR   GeneID; 7704; -.
DR   KEGG; hsa:7704; -.
DR   MANE-Select; ENST00000335953.9; ENSP00000338157.4; NM_006006.6; NP_005997.2.
DR   UCSC; uc001pop.4; human. [Q05516-1]
DR   AGR; HGNC:12930; -.
DR   CTD; 7704; -.
DR   DisGeNET; 7704; -.
DR   GeneCards; ZBTB16; -.
DR   HGNC; HGNC:12930; ZBTB16.
DR   HPA; ENSG00000109906; Tissue enhanced (tongue).
DR   MalaCards; ZBTB16; -.
DR   MIM; 176797; gene.
DR   MIM; 612447; phenotype.
DR   neXtProt; NX_Q05516; -.
DR   OpenTargets; ENSG00000109906; -.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   Orphanet; 99861; Precursor T-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA37517; -.
DR   VEuPathDB; HostDB:ENSG00000109906; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000154616; -.
DR   HOGENOM; CLU_026420_0_0_1; -.
DR   InParanoid; Q05516; -.
DR   OMA; TEVKHEM; -.
DR   OrthoDB; 3044976at2759; -.
DR   PhylomeDB; Q05516; -.
DR   TreeFam; TF350825; -.
DR   PathwayCommons; Q05516; -.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q05516; -.
DR   SIGNOR; Q05516; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 7704; 12 hits in 1214 CRISPR screens.
DR   ChiTaRS; ZBTB16; human.
DR   EvolutionaryTrace; Q05516; -.
DR   GeneWiki; Zinc_finger_and_BTB_domain-containing_protein_16; -.
DR   GenomeRNAi; 7704; -.
DR   Pharos; Q05516; Tbio.
DR   PRO; PR:Q05516; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q05516; protein.
DR   Bgee; ENSG00000109906; Expressed in skin of hip and 203 other tissues.
DR   ExpressionAtlas; Q05516; baseline and differential.
DR   Genevisible; Q05516; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl.
DR   GO; GO:0016604; C:nuclear body; IDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IMP:UniProtKB.
DR   GO; GO:0017053; C:transcription repressor complex; IDA:MGI.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001222; F:transcription corepressor binding; IPI:UniProtKB.
DR   GO; GO:0031703; F:type 2 angiotensin receptor binding; IEA:Ensembl.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; NAS:UniProtKB.
DR   GO; GO:0051216; P:cartilage development; IDA:UniProtKB.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; ISS:UniProtKB.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0009880; P:embryonic pattern specification; IEA:Ensembl.
DR   GO; GO:0035136; P:forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; IDA:UniProtKB.
DR   GO; GO:0048133; P:male germ-line stem cell asymmetric division; IEA:Ensembl.
DR   GO; GO:0001823; P:mesonephros development; ISS:UniProtKB.
DR   GO; GO:0030099; P:myeloid cell differentiation; TAS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045638; P:negative regulation of myeloid cell differentiation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0043931; P:ossification involved in bone maturation; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0061036; P:positive regulation of cartilage development; IDA:UniProtKB.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:UniProtKB.
DR   GO; GO:0051138; P:positive regulation of NK T cell differentiation; IEA:Ensembl.
DR   GO; GO:0045778; P:positive regulation of ossification; IDA:UniProtKB.
DR   GO; GO:0034504; P:protein localization to nucleus; IEA:Ensembl.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   CDD; cd18205; BTB_POZ_ZBTB16_PLZF; 1.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 7.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR46105; AGAP004733-PA; 1.
DR   PANTHER; PTHR46105:SF5; AGAP004733-PA; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF00096; zf-C2H2; 3.
DR   Pfam; PF13912; zf-C2H2_6; 2.
DR   SMART; SM00225; BTB; 1.
DR   SMART; SM00355; ZnF_C2H2; 9.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 4.
DR   SUPFAM; SSF54695; POZ domain; 1.
DR   PROSITE; PS50097; BTB; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 8.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 9.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosomal rearrangement;
KW   Disease variant; DNA-binding; Intellectual disability; Metal-binding;
KW   Nucleus; Phosphoprotein; Proto-oncogene; Reference proteome; Repeat;
KW   Repressor; Transcription; Transcription regulation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..673
FT                   /note="Zinc finger and BTB domain-containing protein 16"
FT                   /id="PRO_0000047729"
FT   DOMAIN          34..96
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   ZN_FING         404..426
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         432..454
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         461..483
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         490..512
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         518..540
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         546..568
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         574..596
FT                   /note="C2H2-type 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         602..624
FT                   /note="C2H2-type 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         630..652
FT                   /note="C2H2-type 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          200..300
FT                   /note="Interaction with RUNX1T1"
FT                   /evidence="ECO:0000269|PubMed:10688654"
FT   REGION          215..236
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          249..332
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            394..395
FT                   /note="Breakpoint for translocation to form PLZF-RAR-alpha
FT                   oncogene"
FT   MOD_RES         76
FT                   /note="Phosphoserine; by PDPK1"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         184
FT                   /note="Phosphoserine; by PDPK1"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         197
FT                   /note="Phosphoserine; by PDPK1"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         256
FT                   /note="Phosphoserine; by PDPK1"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         282
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         628
FT                   /note="Phosphoserine; by PDPK1"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         255..377
FT                   /note="Missing (in isoform PLZFA)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006896"
FT   VARIANT         617
FT                   /note="M -> V (in SGYMR; dbSNP:rs121434606)"
FT                   /evidence="ECO:0000269|PubMed:18611983"
FT                   /id="VAR_054912"
FT   CONFLICT        580
FT                   /note="G -> D (in Ref. 1; CAA79489)"
FT                   /evidence="ECO:0000305"
FT   HELIX           16..30
FT                   /evidence="ECO:0007829|PDB:1BUO"
FT   TURN            31..33
FT                   /evidence="ECO:0007829|PDB:1BUO"
FT   STRAND          36..42
FT                   /evidence="ECO:0007829|PDB:1BUO"
FT   STRAND          44..47
FT                   /evidence="ECO:0007829|PDB:1BUO"
FT   HELIX           49..55
FT                   /evidence="ECO:0007829|PDB:1BUO"
FT   HELIX           57..62
FT                   /evidence="ECO:0007829|PDB:1BUO"
FT   HELIX           63..65
FT                   /evidence="ECO:0007829|PDB:1CS3"
FT   STRAND          68..72
FT                   /evidence="ECO:0007829|PDB:1BUO"
FT   HELIX           77..89
FT                   /evidence="ECO:0007829|PDB:1BUO"
FT   HELIX           96..98
FT                   /evidence="ECO:0007829|PDB:1BUO"
FT   HELIX           99..109
FT                   /evidence="ECO:0007829|PDB:1BUO"
FT   HELIX           112..125
FT                   /evidence="ECO:0007829|PDB:1BUO"
SQ   SEQUENCE   673 AA;  74274 MW;  51F8E361FA31239E CRC64;
     MDLTKMGMIQ LQNPSHPTGL LCKANQMRLA GTLCDVVIMV DSQEFHAHRT VLACTSKMFE
     ILFHRNSQHY TLDFLSPKTF QQILEYAYTA TLQAKAEDLD DLLYAAEILE IEYLEEQCLK
     MLETIQASDD NDTEATMADG GAEEEEDRKA RYLKNIFISK HSSEESGYAS VAGQSLPGPM
     VDQSPSVSTS FGLSAMSPTK AAVDSLMTIG QSLLQGTLQP PAGPEEPTLA GGGRHPGVAE
     VKTEMMQVDE VPSQDSPGAA ESSISGGMGD KVEERGKEGP GTPTRSSVIT SARELHYGRE
     ESAEQVPPPA EAGQAPTGRP EHPAPPPEKH LGIYSVLPNH KADAVLSMPS SVTSGLHVQP
     ALAVSMDFST YGGLLPQGFI QRELFSKLGE LAVGMKSESR TIGEQCSVCG VELPDNEAVE
     QHRKLHSGMK TYGCELCGKR FLDSLRLRMH LLAHSAGAKA FVCDQCGAQF SKEDALETHR
     QTHTGTDMAV FCLLCGKRFQ AQSALQQHME VHAGVRSYIC SECNRTFPSH TALKRHLRSH
     TGDHPYECEF CGSCFRDEST LKSHKRIHTG EKPYECNGCG KKFSLKHQLE THYRVHTGEK
     PFECKLCHQR SRDYSAMIKH LRTHNGASPY QCTICTEYCP SLSSMQKHMK GHKPEEIPPD
     WRIEKTYLYL CYV
//
